Australia’s active vaccine safety system
As of Tuesday this week, all Australian adults aged 40-49 are eligible to receive a COVID-19 vaccine.
The Australian Technical Advisory Group on Immunisation (ATAGI) recommends Australians aged 16 years and older have a COVID booster vaccine three months after receiving their second dose.
You now need a third dose to be considered “up to date” with COVID vaccination, previously known as “fully vaccinated”.
Despite this, only about half of the eligible population has received a booster dose.
Many people are wondering how booster side effects compare to the first two doses, when they can get a booster dose after COVID infection, and whether we’ll need more than three doses in the future.
Here we answer some of your COVID booster vaccine questions.
There’s still widespread community transmission of the Omicron variant across Australia and the world.
The protection provided by two doses of a COVID vaccine is reduced and more rapidly wanes against Omicron.
Despite this, many eligible Australians aren’t coming forward for their booster, perhaps reassured by reports that Omicron is milder, so therefore not something to be worried about.
Omicron infections continue to cause significant impact in all Australian states and territories, with more than 2,400 Australians currently hospitalised.
There’s now clear evidence getting your booster shot is the best way to restore protection against infection and severe disease.
Having a booster three months following the primary course can provide similar levels of protection against Omicron as the two primary doses did for Delta.
Australians over 16 can now have Pfizer or Moderna as a booster, regardless of which vaccines you had for the first two.
Pfizer’s is a full dose just like the first two, while Moderna’s booster dose is half the dose of the primary vaccine.
AstraZeneca has been approved as a booster dose, but Pfizer and Moderna remain preferred, except in a small number people who have had a significant adverse reaction to mRNA vaccines.
Novavax, the new protein-based COVID vaccine, is currently only approved for use in the first two doses. Despite encouraging evidence from clinical trials, it’s not currently approved as a booster.
Boosters aren’t yet recommended in younger adolescents (less than 16 years old) and children.
AusVaxSafety, Australia’s national active vaccine safety surveillance system, found Australians who’ve already had their booster vaccine reported similar side effects as they did after their second dose, for both Pfizer and Moderna boosters.
The most common side effect following booster vaccines was a local reaction (including pain, redness, swelling and itching over the injection site), followed by fatigue, headache and muscle or joint pain.
Less than 1% of people reported needing to see a doctor as a result of their side effects.
Fewer people also reported needing to miss work, study or their routine duties as a result of booster vaccine side effects compared to their second dose, suggesting they were manageable.
It’s not uncommon to experience swollen lymph nodes, often in the armpit on the same side as the vaccination shot. This normally occurs within a few days of vaccination and resolves within a week or so without treatment.
Swollen lymph nodes are more common following booster vaccines, with up to 5% of people reporting this following a Pfizer booster, compared to less than 1% of people following dose one or dose two. Swollen lymph nodes were experienced in up to 10% of people following Moderna boosters.
We don’t know why some people experience side effects such as swollen lymph nodes, and others don’t.
There’s a small increased risk of heart inflammation (pericarditis and/or myocarditis) in people who have received an mRNA COVID vaccine (including Pfizer and Moderna), compared to unvaccinated people.
However, COVID infection is associated with a substantially higher risk of myocarditis, and other cardiac complications, compared to a COVID vaccination.
As of February 13, approximately 10 million third doses have been administered in Australia. Only six reports of likely myocarditis and 25 reports of likely pericarditis have been reported to the TGA for Pfizer, and four reports of likely myocarditis and eight reports of likely pericarditis for Moderna.
Data from Israel and US are also reassuring, finding lower rates of myocarditis and pericarditis following a third dose compared to a second dose of mRNA vaccines.
As with vaccination, immunity following COVID infection wanes over time.
That’s why, even if you get COVID, we still recommend you get your next dose to ensure you get the best protection.
You can get vaccinated as soon as you’ve recovered from your COVID infection.
Having COVID will provide some immunity against reinfection, so you can defer vaccination for up to four months after the start of your infection.
If you’ve received antibody medication or convalescent plasma as part of your treatment for COVID, you should defer future vaccine doses for at least three months after infection.
A report published by the US Centers for Disease Control and Prevention (CDC) in February found protection was starting to wane from four months after the third dose.
But it’s too early to tell if further booster vaccines are required in the future.
Whether having a single booster is enough to protect ourselves against future infections is still uncertain at this stage, but scientists, health professionals and policy makers are watching these data very closely.
Ahead of these data, it’s more important than ever to get that booster dose as soon as you’re eligible!
Professor Christopher Blyth is a Paediatrician, Infectious Diseases Physician and Clinical Microbiologist, Telethon Kids Institute, The University of Western Australia
Dr Lucy Deng Paediatrician, NCIRS, Clinical Lecturer, Children's Hospital Westmead Clinical School, University of Sydney
Associate Professor Nick Wood Discipline of Childhood and Adolescent Health, University of Sydney, and Associate Director, NCIRS
This article first appeared in The Conversation. It has been reproduced here under Creative Commons licence.
AusVaxSafety receives fundingfrom the Australian Government
NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090
We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Copyright © 2022 AusVaxSafety. All rights reserved
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.
Stay updated with the latest from NCIRS
Stay updated with the latest from ausvax
We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.